These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27484159)

  • 1. Co-morbid conditions in use of recombinant tissue plasminogen activator (rt-PA) for the treatment of acute ischaemic stroke.
    Nathaniel TI; Cochran T; Chaves J; Fulmer E; Sosa C; Yi S; Fredwall M; Sternberg S; Blackhurst D; Nelson A; Leacock R
    Brain Inj; 2016; 30(10):1261-5. PubMed ID: 27484159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation.
    Lawson TR; Brown IE; Westerkam DL; Blackhurst DW; Sternberg S; Leacock R; Nathaniel TI
    Restor Neurol Neurosci; 2015; 33(3):301-8. PubMed ID: 25698111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: an audit of current practice and clinical outcomes.
    Williams JM; Navin TJ; Jude MR; Levi CR
    Aust J Rural Health; 2013 Aug; 21(4):203-7. PubMed ID: 24033520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use.
    Lin SY; Tang SC; Tsai LK; Yeh SJ; Hsiao YJ; Chen YW; Chen KH; Yip BS; Shen LJ; Wu FL; Jeng JS
    Eur J Neurol; 2014 Oct; 21(10):1285-91. PubMed ID: 24909847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment.
    Huang Y; Sharma VK; Robinson T; Lindley RI; Chen X; Kim JS; Lavados P; Olavarría V; Arima H; Fuentes S; Nguyen HT; Lee TH; Parsons MW; Levi C; Demchuk AM; Bath PM; Broderick JP; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Pandian J; Ricci S; Stapf C; Woodward M; Wang J; Chalmers J; Anderson CS;
    Int J Stroke; 2015 Jul; 10(5):778-88. PubMed ID: 25832995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of intravenous recombinant tissue plasminogen activator for acute ischemic stroke in patients aged over 80 years.
    Mione G; Ducrocq X; Thilly N; Lacour JC; Vespignani H; Richard S
    Geriatr Gerontol Int; 2016 Jul; 16(7):843-9. PubMed ID: 26245693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
    Betts KA; Hurley D; Song J; Sajeev G; Guo J; Du EX; Paschoalin M; Wu EQ
    J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):1996-2003. PubMed ID: 28689999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of intravenous thrombolysis in 3-4.5 hours: analysis of the Minnesota stroke registry.
    Tekle WG; Chaudhry SA; Hassan AE; Peacock JM; Lakshminarayan K; Tsai A; Luepker R; Anderson DC; Qureshi AI
    Cerebrovasc Dis; 2012; 34(5-6):400-5. PubMed ID: 23221276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action.
    Bhatia R; Hill MD; Shobha N; Menon B; Bal S; Kochar P; Watson T; Goyal M; Demchuk AM
    Stroke; 2010 Oct; 41(10):2254-8. PubMed ID: 20829513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use and in-hospital outcomes of recombinant tissue plasminogen activator in pediatric arterial ischemic stroke patients.
    Nasr DM; Biller J; Rabinstein AA
    Pediatr Neurol; 2014 Nov; 51(5):624-31. PubMed ID: 25194722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
    Yan X; Hu HT; Liu S; Sun YH; Gao X
    Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Estimation of patient eligibility for thrombolysis in acute ischaemic stroke based on a hospital stroke registry in Warsaw].
    Kobayashi A; Sarzyńska-Długosz I; Niewada M; Skowrońska M; Członkowska A
    Neurol Neurochir Pol; 2006; 40(5):369-75. PubMed ID: 17103349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with the administration of tissue plasminogen activator for acute ischemic stroke.
    Kunisawa S; Kobayashi D; Lee J; Otsubo T; Ikai H; Yokota C; Minematsu K; Imanaka Y
    J Stroke Cerebrovasc Dis; 2014 Apr; 23(4):724-31. PubMed ID: 23910512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
    Lee SH; Kim BJ; Han MK; Park TH; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Nah HW; Lee J; Lee SJ; Ko Y; Kim JG; Park JM; Kang K; Cho YJ; Hong KS; Choi JC; Kim JT; Choi K; Kim DE; Ryu WS; Kim WJ; Shin DI; Yeo M; Lee J; Lee JS; Gorelick PB; Bae HJ
    Int J Stroke; 2016 Oct; 11(7):783-90. PubMed ID: 27312681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke thrombolysis in England: an age stratified analysis of practice and outcome.
    Bray BD; Campbell J; Hoffman A; Tyrrell PJ; Wolfe CD; Rudd AG
    Age Ageing; 2013 Mar; 42(2):240-5. PubMed ID: 23174425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate.
    Kleindorfer D; Lindsell CJ; Brass L; Koroshetz W; Broderick JP
    Stroke; 2008 Mar; 39(3):924-8. PubMed ID: 18239184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombolysis safety and effectiveness in acute ischemic stroke patients with pre-morbid disability.
    Caruso P; Ajčević M; Furlanis G; Ridolfi M; Lugnan C; Cillotto T; Naccarato M; Manganotti P
    J Clin Neurosci; 2020 Feb; 72():180-184. PubMed ID: 31875830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset.
    Lorenzano S; Toni D;
    Int J Stroke; 2012 Apr; 7(3):250-7. PubMed ID: 22292526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with early recanalization failure following intravenous rt-PA therapy for ischemic stroke.
    Koga M; Arihiro S; Miyashita F; Yamamoto H; Yamada N; Nagatsuka K; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2013; 36(4):299-305. PubMed ID: 24135558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.